-
SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China
•
SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a licensing agreement with Italy-based Menarini Group regarding the latter’s novel drug Vaborem (meropenem). Under the agreement, SciClone will obtain development, regulatory, and commercialization rights to the antibacterial drug in China. SciClone will pay Menarini Group…
-
Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment
•
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate ZGGS18. The molecule will be assessed as a treatment for general advanced solid tumors. Drug DetailsZGGS18 is a bispecific antibody (BsAb) targeting vascular…
-
Fortune Care Raises Hundreds of Millions in Series B for Elderly Care Expansion
•
Fushoukang (Shanghai) Family Services Co., Ltd, also known as Fortune Care, a Shanghai-based smart elderly care services provider empowered by information technology, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. This follows a Series B round held in December last year, which raised “tens…
-
Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds
•
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for its bioresorbable scaffolds (BRS) product BIOHEART in coronary heart disease has reached its pre-set primary endpoint. Study DetailsThe prospective, multi-center, randomized-controlled study enrolled 431 patients, with Abbott Laboratories’ Xience everolimus-eluting coronary stent as the control.…
-
Sihuan Pharmaceutical Restructures with Dual Organization Model
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a dual organization structure consisting of group headquarters and business platform headquarters. Its subsidiaries Xuanzhu Biopharm Co., Ltd and Jilin Huisheng Biopharmaceutical Co., Ltd, two biopharmaceutical companies, will establish themselves as the new business platform headquarters.…
-
Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China
•
China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with the China unit of Japan-based Takeda Pharmaceutical Co., Ltd. The financial details of the deal were not disclosed. The partnership aims to boost the commercialization of Takeda’s Takepron (lansoprazole), Pantoloc (pantoprazole), and Prevacid (lansoprazole) in…
-
Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention
•
The Center for Drug Evaluation (CDE) website indicates that Shanghai Belief-Delivery BioMed Co., Ltd’s injectable BBM-H901 has been granted breakthrough therapy designation (BTD) status. The drug is approved for use in preventing bleeding in adult male patients with hemophilia B (congenital factor IX deficiency). Drug DetailsBBM-H901 is a Category 1…
-
Wyze Biotech Raises RMB59m to Advance DNT Cell Therapies
•
Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly raised RMB59 million (USD8.7 million) in a Series A + financing round. The round was led by Utrust Fund and Baidu Venture, among others. The proceeds will support the research and development of off-the-shelf universal…
